Clinuvel Pharmaceuticals Limited (CUV.AX)
AUD 10.76
(0.19%)
AUD 10.76
(0.19%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 35.63 Million AUD | 16.44% |
| 2023 | 30.6 Million AUD | 46.58% |
| 2022 | 20.87 Million AUD | -15.57% |
| 2021 | 24.72 Million AUD | 48.55% |
| 2020 | 16.64 Million AUD | -8.2% |
| 2019 | 18.13 Million AUD | 37.13% |
| 2018 | 13.22 Million AUD | 84.16% |
| 2017 | 7.18 Million AUD | 330.07% |
| 2016 | -3.12 Million AUD | 69.98% |
| 2015 | -10.39 Million AUD | -88.17% |
| 2014 | -5.52 Million AUD | 18.77% |
| 2013 | -6.8 Million AUD | 30.35% |
| 2012 | -9.76 Million AUD | 14.39% |
| 2011 | -11.4 Million AUD | 0.97% |
| 2010 | -11.52 Million AUD | 25.06% |
| 2009 | -15.37 Million AUD | -4.89% |
| 2008 | -14.65 Million AUD | -59.72% |
| 2007 | -9.17 Million AUD | 14.79% |
| 2006 | -10.76 Million AUD | 2.36% |
| 2005 | -11.02 Million AUD | -45.32% |
| 2004 | -7.58 Million AUD | -90.85% |
| 2003 | -3.97 Million AUD | -26.61% |
| 2002 | -3.14 Million AUD | -101.6% |
| 2001 | -1.55 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | 35.63 Million AUD | 16.44% |
| 2024 Q2 | 10.93 Million AUD | 0.0% |
| 2024 Q4 | 24.7 Million AUD | 0.0% |
| 2023 Q4 | 19.21 Million AUD | 0.0% |
| 2023 FY | 30.6 Million AUD | 46.58% |
| 2023 Q2 | 11.38 Million AUD | 0.0% |
| 2022 FY | 20.87 Million AUD | -15.57% |
| 2022 Q2 | 5.87 Million AUD | 0.0% |
| 2022 Q4 | 15 Million AUD | 0.0% |
| 2021 FY | 24.72 Million AUD | 48.55% |
| 2021 Q2 | 6.48 Million AUD | 0.0% |
| 2021 Q4 | 18.24 Million AUD | 0.0% |
| 2020 Q4 | 15.58 Million AUD | 0.0% |
| 2020 Q2 | 1.05 Million AUD | 0.0% |
| 2020 FY | 16.64 Million AUD | -8.2% |
| 2019 Q2 | 4.07 Million AUD | 0.0% |
| 2019 Q4 | 14.05 Million AUD | 0.0% |
| 2019 FY | 18.13 Million AUD | 37.13% |
| 2018 FY | 13.22 Million AUD | 84.16% |
| 2018 Q4 | 11.78 Million AUD | 0.0% |
| 2018 Q2 | 1.44 Million AUD | 0.0% |
| 2017 Q2 | 2.55 Million AUD | 0.0% |
| 2017 FY | 7.18 Million AUD | 330.07% |
| 2017 Q4 | 4.62 Million AUD | 0.0% |
| 2016 Q4 | 125.83 Thousand AUD | 0.0% |
| 2016 FY | -3.12 Million AUD | 69.98% |
| 2016 Q2 | -3.24 Million AUD | 0.0% |
| 2015 FY | -10.39 Million AUD | -88.17% |
| 2015 Q4 | -3.05 Million AUD | 0.0% |
| 2015 Q2 | -7.34 Million AUD | 0.0% |
| 2014 Q2 | -3.21 Million AUD | 0.0% |
| 2014 Q4 | -2.31 Million AUD | 0.0% |
| 2014 FY | -5.52 Million AUD | 18.77% |
| 2013 Q3 | -1.7 Million AUD | 60.35% |
| 2013 Q4 | -2.51 Million AUD | -47.78% |
| 2013 FY | -6.8 Million AUD | 30.35% |
| 2013 Q1 | -2.44 Million AUD | 0.0% |
| 2013 Q2 | -4.28 Million AUD | -75.67% |
| 2012 Q2 | -2.44 Million AUD | 14.39% |
| 2012 FY | -9.76 Million AUD | 14.39% |
| 2012 Q4 | -2.44 Million AUD | 0.0% |
| 2012 Q3 | -2.44 Million AUD | 0.0% |
| 2012 Q1 | -2.85 Million AUD | 0.0% |
| 2011 Q1 | -2.88 Million AUD | 0.0% |
| 2011 Q2 | -2.85 Million AUD | 0.97% |
| 2011 FY | -11.4 Million AUD | 0.97% |
| 2011 Q3 | -2.85 Million AUD | 0.0% |
| 2011 Q4 | -2.85 Million AUD | 0.0% |
| 2010 Q2 | -2.88 Million AUD | 25.06% |
| 2010 Q4 | -2.88 Million AUD | 0.0% |
| 2010 FY | -11.52 Million AUD | 25.06% |
| 2010 Q1 | -3.84 Million AUD | 0.0% |
| 2010 Q3 | -2.88 Million AUD | 0.0% |
| 2009 Q1 | -3.66 Million AUD | 0.0% |
| 2009 Q3 | -3.84 Million AUD | 0.0% |
| 2009 Q2 | -3.84 Million AUD | -4.89% |
| 2009 Q4 | -3.84 Million AUD | 0.0% |
| 2009 FY | -15.37 Million AUD | -4.89% |
| 2008 Q2 | -3.66 Million AUD | -59.72% |
| 2008 Q1 | -2.29 Million AUD | 0.0% |
| 2008 FY | -14.65 Million AUD | -59.72% |
| 2008 Q4 | -3.66 Million AUD | 0.0% |
| 2008 Q3 | -3.66 Million AUD | 0.0% |
| 2007 Q3 | -2.29 Million AUD | 0.0% |
| 2007 Q2 | -2.29 Million AUD | 14.79% |
| 2007 FY | -9.17 Million AUD | 14.79% |
| 2007 Q1 | -2.69 Million AUD | 0.0% |
| 2007 Q4 | -2.29 Million AUD | 0.0% |
| 2006 FY | -10.76 Million AUD | 2.36% |
| 2006 Q3 | -2.69 Million AUD | 0.0% |
| 2006 Q1 | -2.75 Million AUD | 0.0% |
| 2006 Q4 | -2.69 Million AUD | 0.0% |
| 2006 Q2 | -2.69 Million AUD | 2.36% |
| 2005 Q2 | -2.75 Million AUD | 0.0% |
| 2005 Q4 | -2.75 Million AUD | 0.0% |
| 2005 Q3 | -2.75 Million AUD | 0.0% |
| 2005 Q1 | - AUD | 0.0% |
| 2005 FY | -11.02 Million AUD | -45.32% |
| 2004 Q3 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | -7.58 Million AUD | -90.85% |
| 2004 Q1 | -994.19 Thousand AUD | 0.0% |
| 2004 Q2 | - AUD | 100.0% |
| 2003 Q1 | -785.3 Thousand AUD | 0.0% |
| 2003 FY | -3.97 Million AUD | -26.61% |
| 2003 Q3 | -994.19 Thousand AUD | 0.0% |
| 2003 Q4 | -994.19 Thousand AUD | 0.0% |
| 2003 Q2 | -994.19 Thousand AUD | -26.6% |
| 2002 Q3 | -785.3 Thousand AUD | 0.0% |
| 2002 Q2 | -785.3 Thousand AUD | -101.67% |
| 2002 Q4 | -785.3 Thousand AUD | 0.0% |
| 2002 Q1 | -389.39 Thousand AUD | 0.0% |
| 2002 FY | -3.14 Million AUD | -101.6% |
| 2001 Q3 | -389.39 Thousand AUD | 0.0% |
| 2001 Q2 | -389.39 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | -1.55 Million AUD | 0.0% |
| 2001 Q4 | -389.39 Thousand AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | 762.23% |
| Acrux Limited | -5.8 Million AUD | 714.42% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 356.937% |
| BTC Health Limited | 1.05 Million AUD | -3276.935% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 384.412% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 184.198% |
| Biome Australia Limited | -1.67 Million AUD | 2233.656% |
| Hexima Limited | -933.87 Thousand AUD | 3915.975% |
| Immutep Limited | -39.89 Million AUD | 189.322% |
| Memphasys Limited | -4.44 Million AUD | 902.256% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 77.313% |
| Noxopharm Limited | -3.57 Million AUD | 1095.953% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 532.583% |
| Race Oncology Limited | -13.81 Million AUD | 357.873% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 174.321% |
| Starpharma Holdings Limited | -8.16 Million AUD | 536.453% |
| Tissue Repair Ltd | -4.13 Million AUD | 961.176% |
| Biotron Limited | -3.43 Million AUD | 1136.989% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 286.349% |
| CSL Limited | 2.64 Billion AUD | 98.651% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | -411.687% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 2555.577% |
| Bio-Gene Technology Limited | -2.4 Million AUD | 1579.191% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 197.45% |
| Patrys Limited | -3.53 Million AUD | 1106.919% |
| Orthocell Limited | -7.18 Million AUD | 596.262% |
| Imugene Limited | -149.68 Million AUD | 123.808% |
| PYC Therapeutics Limited | -37.72 Million AUD | 194.462% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | 658.895% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 465.7% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 507.457% |
| Nanollose Limited | -1.15 Million AUD | 3181.256% |
| Invex Therapeutics Ltd | -1.64 Million AUD | 2270.554% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | -10891.752% |
| Amplia Therapeutics Limited | -4.5 Million AUD | 891.312% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | 1344.148% |
| Nyrada Inc. | -1.38 Million AUD | 2670.745% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | -583.868% |
| Dimerix Limited | -17.07 Million AUD | 308.704% |
| PharmAust Limited | -9.03 Million AUD | 494.541% |
| AnteoTech Limited | -8.88 Million AUD | 501.287% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 160.758% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 301.772% |
| Avecho Biotechnology Limited | -3.43 Million AUD | 1136.977% |
| Actinogen Medical Limited | -13.04 Million AUD | 373.195% |
| Immuron Limited | -6.93 Million AUD | 613.717% |
| Argenica Therapeutics Limited | -5.47 Million AUD | 750.359% |